AtriCure, Inc.

NasdaqGM:ATRC Stock Report

Market Cap: US$2.7b

AtriCure Valuation

Is ATRC undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ATRC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: ATRC ($53.03) is trading above our estimate of future cash flow value ($0.73)

Significantly Below Future Cash Flow Value: ATRC is trading above our estimate of future cash flow value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ATRC?

Key metric: As ATRC is barely profitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for ATRC. This is calculated by dividing ATRC's market cap by their current revenue.
What is ATRC's PS Ratio?
PS Ratio4.7x
SalesUS$569.62m
Market CapUS$2.73b

Price to Sales Ratio vs Peers

How does ATRC's PS Ratio compare to its peers?

The above table shows the PS ratio for ATRC vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average9.3x
AXGN Axogen
10.1x16.44%US$2.5b
NVCR NovoCure
2.6x16.27%US$2.0b
BFLY Butterfly Network
17.7x24.67%US$2.0b
LMAT LeMaitre Vascular
6.9x8.49%US$1.8b
ATRC AtriCure
4.7x11.07%US$2.7b

Price-To-Sales vs Peers: ATRC is good value based on its Price-To-Sales Ratio (4.7x) compared to the peer average (9.3x).

Historical Price to Sales Ratio

Historical Price to Sales Ratio compares a stock's price to its sales over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Sales Ratio vs Industry

How does ATRC's PS Ratio compare vs other companies in the US Medical Equipment Industry?

54 CompaniesPrice / SalesEstimated GrowthMarket Cap
XRAY DENTSPLY SIRONA
0.6x1.54%US$2.19b
ENOV Enovis
0.5x4.63%US$1.15b
QDEL QuidelOrtho
0.3x1.26%US$917.54m
OFIX Orthofix Medical
0.4x3.62%US$372.70m
ATRC 4.7xIndustry Avg. 3.0xNo. of Companies54PS02.85.68.411.214+
54 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: ATRC is expensive based on its Price-To-Sales Ratio (4.7x) compared to the US Medical Equipment industry average (3x).

Price to Sales Ratio vs Fair Ratio

What is ATRC's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ATRC PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio4.7x
Fair PS Ratio4.2x

Price-To-Sales vs Fair Ratio: ATRC is expensive based on its Price-To-Sales Ratio (4.7x) compared to the estimated Fair Price-To-Sales Ratio (4.2x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst ATRC forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$53.03
US$51.67
-2.57%
15.40%US$64.00US$36.00n/a9
Sep ’27US$48.92
US$49.56
+1.30%
13.82%US$60.00US$36.00n/a9
Aug ’27US$37.76
US$47.33
+25.35%
11.36%US$55.00US$36.00n/a9
Jul ’27US$29.73
US$47.00
+58.09%
11.94%US$55.00US$36.00n/a8
Jun ’27US$26.48
US$47.00
+77.49%
11.94%US$55.00US$36.00n/a8
May ’27US$29.02
US$46.75
+61.10%
11.31%US$53.00US$36.00n/a8
Apr ’27US$28.31
US$47.88
+69.11%
11.97%US$54.00US$36.00n/a8
Mar ’27US$31.26
US$49.38
+57.95%
11.81%US$55.00US$36.00n/a8
Feb ’27US$36.93
US$52.78
+42.91%
12.75%US$64.00US$44.00n/a9
Jan ’27US$39.56
US$52.33
+32.29%
14.13%US$64.00US$40.00n/a9
Dec ’26US$35.09
US$51.67
+47.24%
15.48%US$64.00US$40.00n/a9
Nov ’26US$34.55
US$51.67
+49.54%
15.48%US$64.00US$40.00n/a9
Oct ’26US$34.23
US$50.00
+46.07%
13.03%US$60.00US$40.00n/a9
Sep ’26US$36.99
US$50.00
+35.17%
13.03%US$60.00US$40.00US$48.929
Aug ’26US$34.41
US$50.00
+45.31%
13.03%US$60.00US$40.00US$37.769
Jul ’26US$32.20
US$49.89
+54.93%
12.04%US$60.00US$40.00US$29.739
Jun ’26US$34.57
US$49.89
+44.31%
12.04%US$60.00US$40.00US$26.489
May ’26US$29.29
US$49.89
+70.33%
12.04%US$60.00US$40.00US$29.029
Apr ’26US$33.36
US$52.22
+56.54%
10.48%US$60.00US$45.00US$28.319
Mar ’26US$38.74
US$54.22
+39.96%
11.91%US$66.00US$45.00US$31.269
Feb ’26US$39.87
US$46.33
+16.21%
20.37%US$61.00US$36.00US$36.939
Jan ’26US$30.56
US$45.11
+47.61%
20.99%US$61.00US$36.00US$39.569
Dec ’25US$36.16
US$44.22
+22.30%
18.61%US$60.00US$36.00US$35.099
Nov ’25US$33.51
US$44.22
+31.97%
18.61%US$60.00US$36.00US$34.559
Oct ’25US$27.80
US$39.89
+43.49%
27.35%US$60.00US$26.00US$34.239
Sep ’25US$26.21
US$39.89
+52.19%
27.35%US$60.00US$26.00US$36.999
US$51.67
Fair Value
2.6% overvalued intrinsic discount
9
Number of Analysts

Analyst Forecast: Target price is lower than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/09 22:45
End of Day Share Price 2026/09/09 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

AtriCure, Inc. is covered by 19 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Charley JonesBarrington Research Associates, Inc.
Marie ThibaultBTIG
Michael GormanBTIG